+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 29Days - 18Years
All Genders
ID04850456

Evaluating Human Gamma Globulin Treatment in Children With Severe Infection and Inflammatory Storms in Intensive Care

Led by Children's Hospital of Fudan University · Updated on 2026-03-16

200

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Critically ill children experiencing inflammatory storms may face severe immune damage, which can lead to multiple organ failure or death. This research aims to understand how human gamma globulin therapy might help control these inflammatory storms in severely infected children. The study is observational and seeks to provide reliable data to guide clinical use of gamma globulin in intensive care settings. The research compares children treated with human gamma globulin to those receiving conventional treatment in a pediatric intensive care unit. It retrospectively collects clinical and demographic data from electronic health records to evaluate the effectiveness and suitability of gamma globulin therapy. The study focuses on children hospitalized with severe infection complicated by inflammatory storms. Participants outcomes such as death rate within 28 days after discharge from the pediatric intensive care unit and length of stay in the unit will be measured. Additional immune and inflammatory markers including CD4CD8, C-reactive protein, and various interleukins will be assessed within 3 to 15 days after starting treatment. The study will help clinicians and pharmacists make informed decisions on gamma globulin use in this critically ill population.

CONDITIONS

Brief Title

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm

Research Team

G

Guoping Lu, Doctor

Y

Yao Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here